Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for producing a stable ~~adhesion~~ cell ~~lines~~ line of mammalian neural precursor cells *in vitro*, comprising the steps of:

a) preparing an adhesion culture of neural precursor cells in a serum-free medium;

~~b) culturing the neural precursor cells in the presence of~~ including a first mitogen, ~~wherein said first mitogen is~~ selected from the group consisting of aFGF, bFGF, EGF, TGFα and combinations thereof;

c) introducing a c-myc construct into ~~the~~ a cell ~~cells~~ of the adhesion culture in serum-free medium including the first mitogen,

wherein the c-myc construct is comprised of a c-myc cDNA fused with at least one element selected from the group consisting of DNA for a ligand binding domain for an estrogen receptor, an androgen receptor, a progesterone receptor, a glucocorticoid receptor, a thyroid hormone receptor, a retinoid receptor, and an ecdysone receptor; and

d) ~~further~~ culturing the cells including the c-myc construct in a medium containing the first mitogen and a second mitogen,

wherein said second mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGFα, serum and combinations thereof, with the proviso that the second mitogen is other than the first mitogen,

wherein said medium containing the first mitogen and the second mitogen further comprises a myc-activating chemical selected from the group consisting of β-estradiol, RU38486, dexamethasone, thyroid hormones, retinoids, and ecdysone.

Claims 2-3 (canceled).

Claim 4 (original): The method of claim 1, wherein the mammalian neural precursor cells are derived from a human.

Claim 5 (original): The method of claim 1, wherein the mammalian neural precursor cells are derived from an *in vitro* culture of pluripotent embryonic stem cells.

Claims 6-11 (canceled).

Claim 12 (currently amended): A method for producing a stable ~~adhesion~~ clonal cell ~~lines~~ line of mammalian neural precursor cells *in vitro*, comprising the steps of:

a) preparing an adhesion culture of neural precursor cells in a serum-free medium;

~~b) culturing the neural precursor cells in the presence of~~ including a first mitogen, ~~wherein said first mitogen is~~ selected from the group consisting of aFGF, bFGF, EGF, TGFα and combinations thereof;

c) introducing a c-myc construct and a selectable marker into ~~the cells~~ a cell of the adhesion culture in serum-free medium including the first mitogen,

wherein the c-myc construct is comprised of a c-myc cDNA fused with at least one element selected from the group consisting of DNA for a ligand binding domain for an estrogen receptor, an androgen receptor, a progesterone receptor, a glucocorticoid receptor, a thyroid hormone receptor, a retinoid receptor, and an ecdysone receptor;

d) ~~further~~ culturing the cells including the c-myc construct in a medium containing the first mitogen and a second mitogen, wherein said second mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGFα and combinations thereof, with the proviso that the second mitogen is other than the first mitogen,

wherein said medium containing the first mitogen and the second mitogen further comprises a myc-activating chemical selected from the group consisting of β-estradiol, RU38486, dexamethasone, thyroid hormones, retinoids, and ecdysone; and

e) collecting c-myc treated cells and co-culturing them with feeder cells free of the selectable marker and capable of supporting survival of the c-myc treated cells in a medium containing the first mitogen and the second mitogen, with the proviso that the second mitogen is other than the first mitogen.

Claims 13-14 (canceled).

Claim 15 (original): The method of claim 12, wherein the mammalian neural precursor cells are derived from a human.

Claim 16 (original): The method of claim 12, wherein the mammalian neural precursor cells are derived from an *in vitro* culture of pluripotent embryonic stem cells.

Claims 17-22 (canceled).